Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Clario and the University of Oxford's NeuroMetrology Lab Advance Parkinson's Disease Research with the Opal® Wearable Sensor System

This image opens in the lightbox

News provided by

Clario

06 Oct, 2025, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

  • Clario partners with the University of Oxford's NeuroMetrology Lab to transform Parkinson's disease research with the Opal® wearable sensor system.
  • Partnership to advance clinical trial endpoints by improving identification of disease progression and movement-based endpoints.
  • Digital endpoints of gait and balance combined with machine learning enable earlier detection of motor symptom progression.
  • Opal sensors can predict the risk of falls in Parkinson's patients with up to 92% accuracy two years in advance and 78% accuracy five years in advance.

PHILADELPHIA, Oct. 6, 2025 /PRNewswire/ -- Clario, a leading provider of endpoint data solutions for clinical trials, today announced the enrollment of the first participant in its collaboration with the University of Oxford's NeuroMetrology Lab, led by Professor Chrystalina Antoniades. The partnership is focused on advancing the use of Clario's Opal® wearable sensor system to enhance Parkinson's disease (PD) research by enabling more precise measurement of motor symptoms and disease progression.

The Opal® wearable sensor collects detailed, objective movement data through single- or multi-sensor setups, enabling the detection of subtle but meaningful changes in gait, balance, and mobility with a level of precision that surpasses traditional assessment methods. The NeuroMetrology Lab's groundbreaking work, powered by Opal's cutting-edge movement analysis capabilities, improves monitoring of disease progression and predicts adverse events such as falls, which represent a significant cause of disability and reduced quality of life in PD patients.

Findings from Professor Antoniades' team demonstrate the high potential of movement analysis in PD research and pave the way for predictive and preventive healthcare. In a recent study, a 3-minute in-office assessment predicted fall risk for Parkinson's patients with 84–92% accuracy up to two years in advance and 78% accuracy up to five years in advance. These predictive capabilities may change how the disease is managed and provide greater opportunity to evaluate therapeutic efficacy in clinical studies.

"Our collaboration with Professor Antoniades and her team is an exciting step forward in Parkinson's research," said Ellen Street, Executive Vice President and General Manager, Digital Physiology at Clario. "The team's research combined with the unique capabilities of the Opal device can improve monitoring of disease progression and enable a greater ability to understand the effect of a drug candidate in Parkinson's patients. It perfectly embodies Clario's mission to transform lives by unlocking better evidence."

"We are excited to partner with Clario to enhance Parkinson's research using Opal's advanced movement analysis," said Professor Antoniades. "This collaboration will refine predictive models for fall risk and disease progression, improving patient outcomes. There is a crucial need for regulatory-approved digital movement endpoints in clinical trials to assess Parkinson's therapies accurately. Integrating validated, objective measures into drug development will enable precise evaluation and accelerate optimized treatments for patients."

This phase of the collaboration between Clario and the NeuroMetrology Lab will determine the usability and effectiveness of Opal data collected in remote settings via prescribed tasks in the home and real-world passive mobility monitoring, powered by Mobilise-D Digital Mobility Outcomes that Clario now offers.

To learn more about Clario and its wearable sensor technologies, please visit Clario.com.

About Clario

Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion, and respiratory endpoints.

For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported over 30,000 clinical trial opportunities in more than 100 countries. Our global team of science, technology, and operational experts have supported over 70% of FDA and EMA new drug approvals since 2015.

For more information, go to Clario.com or follow us on LinkedIn.

Media Contact:

media@clario.com

About University of Oxford's NeuroMetrology Lab

The NeuroMetrology Lab at the University of Oxford, directed by Professor Chrystalina Antoniades, is dedicated to developing objective, quantitative tools to measure neurological function. By combining cutting-edge sensor technology, neurophysiology, and clinical neuroscience, the lab aims to improve the detection, monitoring, and treatment of movement disorders such as Parkinson's disease. Its interdisciplinary approach bridges academic research, clinical practice, and industry collaboration to accelerate the translation of scientific discoveries into real-world patient benefit.

https://www.oxquip.co.uk/

https://www.linkedin.com/company/neurometrology-lab/

About the Nuffield Department of Clinical Neurosciences

www.ndcn.ox.ac.uk

About Oxford University

www.ox.ac.uk

Logo - https://mma.prnewswire.com/media/1677749/Clario_Logo.jpg 

Modal title

Also from this source

Clario Announces Completion of Acquisition of WCG's eCOA Business

Clario Announces Completion of Acquisition of WCG's eCOA Business

Clario, a leading provider of digital endpoint data solutions to the clinical trial industry today announced completion of its acquisition of WCG's...

Clario Collaborates with AWS to Push New Boundaries in Clinical Data Analysis with Generative AI

Clario Collaborates with AWS to Push New Boundaries in Clinical Data Analysis with Generative AI

Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced a multi-year agreement with Amazon Web Services ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Computer & Electronics

Computer & Electronics

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • PR Newswire Amplify™
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.